1. Home
  2. RIGL vs ORN Comparison

RIGL vs ORN Comparison

Compare RIGL & ORN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • ORN
  • Stock Information
  • Founded
  • RIGL 1996
  • ORN 1994
  • Country
  • RIGL United States
  • ORN United States
  • Employees
  • RIGL N/A
  • ORN N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • ORN Military/Government/Technical
  • Sector
  • RIGL Health Care
  • ORN Industrials
  • Exchange
  • RIGL Nasdaq
  • ORN Nasdaq
  • Market Cap
  • RIGL 335.5M
  • ORN 339.4M
  • IPO Year
  • RIGL 2000
  • ORN 2007
  • Fundamental
  • Price
  • RIGL $38.85
  • ORN $7.44
  • Analyst Decision
  • RIGL Buy
  • ORN Strong Buy
  • Analyst Count
  • RIGL 5
  • ORN 2
  • Target Price
  • RIGL $38.20
  • ORN $11.25
  • AVG Volume (30 Days)
  • RIGL 995.6K
  • ORN 425.7K
  • Earning Date
  • RIGL 08-05-2025
  • ORN 10-29-2025
  • Dividend Yield
  • RIGL N/A
  • ORN N/A
  • EPS Growth
  • RIGL N/A
  • ORN N/A
  • EPS
  • RIGL 5.43
  • ORN 0.27
  • Revenue
  • RIGL $267,921,000.00
  • ORN $837,494,000.00
  • Revenue This Year
  • RIGL $59.93
  • ORN $4.83
  • Revenue Next Year
  • RIGL N/A
  • ORN $8.34
  • P/E Ratio
  • RIGL $7.15
  • ORN $26.98
  • Revenue Growth
  • RIGL 105.62
  • ORN 15.85
  • 52 Week Low
  • RIGL $12.66
  • ORN $4.64
  • 52 Week High
  • RIGL $43.72
  • ORN $9.95
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 68.57
  • ORN 51.54
  • Support Level
  • RIGL $39.00
  • ORN $6.88
  • Resistance Level
  • RIGL $42.08
  • ORN $7.67
  • Average True Range (ATR)
  • RIGL 2.32
  • ORN 0.30
  • MACD
  • RIGL -0.37
  • ORN 0.14
  • Stochastic Oscillator
  • RIGL 53.26
  • ORN 80.89

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About ORN Orion Group Holdings Inc. Common

Orion Group Holdings Inc is a specialty construction company serving the infrastructure, industrial, and building sectors, providing services both on and off the water in the continental United States, Alaska, Canada and the Caribbean Basin through its marine segment and its concrete segment. Its marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar and mesh across the light commercial, structural and other associated business areas.

Share on Social Networks: